arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Vaxcyte, Inc.

PCVX Health Care Biotechnology: Pharmaceutical Preparations
$61.23
▲ +0.1% Today
as of Sep 4, 16:53 ET
Last 30 days +12.01% Jul 28 → Sep 04
$52.15 $55.15 $58.14 $61.13 $64.13 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$59.73
High
$61.78
Low
$59.65
Volume
$986,685
Avg Vol
$1M
Mkt Cap
$8.8B
P/E (TTM)
—
Beta
—
52w High
$65.00
52w Low
$30.81
Div Yield
—
Shares Out
$145M

Recent Press Releases & News last 60 days · 6 items

Sep 3 · 21:33 MT Newswires
Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data
Sep 3 · 20:05 PR GlobeNewswire
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Aug 27 · 20:05 PR GlobeNewswire
Vaxcyte to Participate in Upcoming Investor Conferences
▸ Show all 6 press releases & news Free account →

Overview

52-week range
$31
$65
89% of range
Avg surprise (last 3)
-11.5%
Avg reaction (last 2)
+0.9%
50% positive
Latest IV / EM
45%
EM ±7.0% · $60 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.30$-1.90$-1.50$-1.10$-0.70 Actual $-0.70Actual $-0.70Actual $-0.91Actual $-0.85Actual $-1.10Actual $-0.83Actual $-1.04Est $-1.02Actual $-1.22Est $-1.12Actual $-1.56Actual $-2.30Est $-1.86Actual $-1.97 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-321M$-268M$-214M$-161M$-108M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.97 — — — — financials
Wed May 6, 2026Mar/2026 $-2.30 $-1.86 -23.7% -121.2% +2.6% earnings
Tue Sep 30, 2025Sep 2025 $-1.56 — — — — financials
Wed Aug 6, 2025Jun/2025 $-1.22 $-1.12 -8.9% — — earnings
Wed May 7, 2025Mar/2025 $-1.04 $-1.02 -2.0% — -0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.83 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.85 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.91 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.70 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.70 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-303M$-346M—$-242M$-226M$-181M—$-140M
Net income$-284M$-321M—$-213M$-167M$-141M—$-103M
EPS (diluted)$-1.97$-2.30—$-1.56$-1.22$-1.04—$-0.83

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$183M$261M$174M$281M$307M$347M$388M$1.05B
Inventory————————
Total current assets$1.55B$1.81B$1.63B$1.77B$1.72B$1.72B$1.79B$2.21B
Total assets$3.14B$3.35B$3.00B$3.17B$3.31B$3.38B$3.51B$3.56B
Long-term debt————————
Total liabilities$380M$352M$317M$279M$234M$178M$205M$142M
Total equity$2.76B$3.00B$2.69B$2.89B$3.07B$3.20B$3.31B$3.42B

Implied volatility — last 90 days

43%78%112%147%182% Jun 07 — IV 128% · EM ±17.7%Jun 08 — IV 60% · EM ±7.9%Jun 09 — IV 63% · EM ±7.9%Jun 10 — IV 82% · EM ±9.7%Jun 11 — IV 114% · EM ±12.6%Jun 12 — IV 126% · EM ±12.9%Jun 15 — IV 46% · EM ±3.3%Jun 16 — IV 56% · EM ±3.3%Jun 19 — IV 57% · EM ±12.6%Jun 22 — IV 62% · EM ±13.0%Jun 23 — IV 62% · EM ±12.6%Jun 24 — IV 43% · EM ±8.7%Jun 25 — IV 56% · EM ±10.9%Jun 26 — IV 52% · EM ±10.0%Jun 29 — IV 60% · EM ±10.7%Jun 30 — IV 58% · EM ±10.1%Jul 01 — IV 49% · EM ±8.3%Jul 02 — IV 51% · EM ±8.2%Jul 03 — IV 53% · EM ±8.2%Jul 06 — IV 60% · EM ±8.3%Jul 07 — IV 87% · EM ±11.5%Jul 08 — IV 68% · EM ±8.5%Jul 10 — IV 79% · EM ±8.8%Jul 13 — IV 67% · EM ±5.6%Jul 14 — IV 101% · EM ±7.3%Jul 15 — IV 182% · EM ±10.8%Jul 16 — IV 85% · EM ±3.6%Jul 20 — IV 59% · EM ±14.1%Jul 21 — IV 59% · EM ±13.7%Jul 22 — IV 56% · EM ±12.9%Jul 23 — IV 55% · EM ±12.4%Jul 24 — IV 55% · EM ±12.2%Jul 27 — IV 57% · EM ±11.9%Jul 28 — IV 57% · EM ±11.6%Jul 29 — IV 60% · EM ±11.9%Jul 30 — IV 57% · EM ±11.1%Jul 31 — IV 58% · EM ±11.0%Aug 03 — IV 60% · EM ±10.7%Aug 04 — IV 59% · EM ±10.2%Aug 05 — IV 61% · EM ±10.1%Aug 06 — IV 50% · EM ±8.0%Aug 07 — IV 52% · EM ±8.1%Aug 10 — IV 51% · EM ±7.0%Aug 11 — IV 50% · EM ±6.6%Aug 12 — IV 48% · EM ±6.0%Aug 13 — IV 49% · EM ±5.8%Aug 14 — IV 51% · EM ±5.6%Aug 17 — IV 52% · EM ±4.4%Aug 18 — IV 52% · EM ±3.8%Aug 19 — IV 66% · EM ±3.9%Aug 20 — IV 71% · EM ±3.0%Aug 24 — IV 56% · EM ±11.8%Aug 25 — IV 48% · EM ±9.8%Aug 26 — IV 47% · EM ±9.4%Aug 27 — IV 46% · EM ±9.0%Aug 28 — IV 44% · EM ±8.5%Aug 31 — IV 46% · EM ±8.2%Sep 01 — IV 46% · EM ±7.9%Sep 02 — IV 47% · EM ±7.9%Sep 03 — IV 44% · EM ±7.2%Sep 04 — IV 45% · EM ±7.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in